NASDAQ:CTSO

Cytosorbents Competitors

$8.90
+0.02 (+0.23 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.67
Now: $8.90
$8.94
50-Day Range
$8.23
MA: $9.10
$11.05
52-Week Range
$6.50
Now: $8.90
$11.74
Volume107,806 shs
Average Volume351,493 shs
Market Capitalization$385.05 million
P/E RatioN/A
Dividend YieldN/A
Beta0.36

Competitors

Cytosorbents (NASDAQ:CTSO) Vs. CSII, MDXG, ATRI, SIBN, TCMD, and LMAT

Should you be buying CTSO stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Cytosorbents, including Cardiovascular Systems (CSII), MiMedx Group (MDXG), Atrion (ATRI), SI-BONE (SIBN), Tactile Systems Technology (TCMD), and LeMaitre Vascular (LMAT).

Cardiovascular Systems (NASDAQ:CSII) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Volatility & Risk

Cardiovascular Systems has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Cardiovascular Systems and Cytosorbents, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Cytosorbents00503.00

Cardiovascular Systems presently has a consensus price target of $47.5714, suggesting a potential upside of 31.67%. Cytosorbents has a consensus price target of $15.00, suggesting a potential upside of 68.54%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Cardiovascular Systems.

Earnings and Valuation

This table compares Cardiovascular Systems and Cytosorbents' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million6.14$-27,240,000.00($0.79)-45.73
Cytosorbents$24.95 million15.43$-19,270,000.00($0.60)-14.83

Cytosorbents has lower revenue, but higher earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cardiovascular Systems and Cytosorbents' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Cytosorbents-30.45%-34.37%-19.74%

Insider and Institutional Ownership

89.7% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 39.8% of Cytosorbents shares are held by institutional investors. 3.0% of Cardiovascular Systems shares are held by company insiders. Comparatively, 5.7% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cardiovascular Systems beats Cytosorbents on 7 of the 13 factors compared between the two stocks.

MiMedx Group (NASDAQ:MDXG) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Profitability

This table compares MiMedx Group and Cytosorbents' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MiMedx Group-37.28%-404.08%-58.81%
Cytosorbents-30.45%-34.37%-19.74%

Institutional and Insider Ownership

4.0% of MiMedx Group shares are owned by institutional investors. Comparatively, 39.8% of Cytosorbents shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Comparatively, 5.7% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares MiMedx Group and Cytosorbents' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$299.26 million4.73$-25,580,000.00N/AN/A
Cytosorbents$24.95 million15.43$-19,270,000.00($0.60)-14.83

Cytosorbents has lower revenue, but higher earnings than MiMedx Group.

Analyst Ratings

This is a breakdown of recent ratings and price targets for MiMedx Group and Cytosorbents, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MiMedx Group00103.00
Cytosorbents00503.00

MiMedx Group presently has a consensus target price of $20.00, indicating a potential upside of 57.23%. Cytosorbents has a consensus target price of $15.00, indicating a potential upside of 68.54%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than MiMedx Group.

Risk & Volatility

MiMedx Group has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Summary

Cytosorbents beats MiMedx Group on 8 of the 12 factors compared between the two stocks.

Cytosorbents (NASDAQ:CTSO) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Cytosorbents and Atrion's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytosorbents$24.95 million15.43$-19,270,000.00($0.60)-14.83
Atrion$155.07 million7.58$36.76 millionN/AN/A

Atrion has higher revenue and earnings than Cytosorbents.

Volatility and Risk

Cytosorbents has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cytosorbents and Atrion, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytosorbents00503.00
Atrion0000N/A

Cytosorbents currently has a consensus price target of $15.00, indicating a potential upside of 68.54%. Given Cytosorbents' higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than Atrion.

Institutional and Insider Ownership

39.8% of Cytosorbents shares are held by institutional investors. Comparatively, 63.2% of Atrion shares are held by institutional investors. 5.7% of Cytosorbents shares are held by company insiders. Comparatively, 22.4% of Atrion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Cytosorbents and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytosorbents-30.45%-34.37%-19.74%
Atrion21.90%13.90%12.55%

Summary

Atrion beats Cytosorbents on 8 of the 12 factors compared between the two stocks.

Cytosorbents (NASDAQ:CTSO) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares Cytosorbents and SI-BONE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytosorbents-30.45%-34.37%-19.74%
SI-BONE-61.67%-45.03%-29.29%

Analyst Ratings

This is a summary of current ratings for Cytosorbents and SI-BONE, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytosorbents00503.00
SI-BONE00503.00

Cytosorbents currently has a consensus price target of $15.00, suggesting a potential upside of 68.54%. SI-BONE has a consensus price target of $32.60, suggesting a potential downside of 3.44%. Given Cytosorbents' higher possible upside, equities research analysts clearly believe Cytosorbents is more favorable than SI-BONE.

Institutional & Insider Ownership

39.8% of Cytosorbents shares are owned by institutional investors. Comparatively, 65.3% of SI-BONE shares are owned by institutional investors. 5.7% of Cytosorbents shares are owned by insiders. Comparatively, 15.5% of SI-BONE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cytosorbents and SI-BONE's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytosorbents$24.95 million15.43$-19,270,000.00($0.60)-14.83
SI-BONE$67.30 million16.42$-38,400,000.00($1.55)-21.78

Cytosorbents has higher earnings, but lower revenue than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cytosorbents has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Tactile Systems Technology (NASDAQ:TCMD) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Tactile Systems Technology and Cytosorbents' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tactile Systems Technology$189.49 million5.59$10.97 million$0.5696.43
Cytosorbents$24.95 million15.43$-19,270,000.00($0.60)-14.83

Tactile Systems Technology has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tactile Systems Technology and Cytosorbents' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tactile Systems Technology-4.57%1.37%0.99%
Cytosorbents-30.45%-34.37%-19.74%

Risk and Volatility

Tactile Systems Technology has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Tactile Systems Technology and Cytosorbents, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tactile Systems Technology01202.67
Cytosorbents00503.00

Tactile Systems Technology currently has a consensus price target of $59.00, suggesting a potential upside of 9.26%. Cytosorbents has a consensus price target of $15.00, suggesting a potential upside of 68.54%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than Tactile Systems Technology.

Insider and Institutional Ownership

39.8% of Cytosorbents shares are held by institutional investors. 5.3% of Tactile Systems Technology shares are held by insiders. Comparatively, 5.7% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LeMaitre Vascular (NASDAQ:LMAT) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Risk & Volatility

LeMaitre Vascular has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.

Earnings and Valuation

This table compares LeMaitre Vascular and Cytosorbents' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LeMaitre Vascular$117.23 million9.01$17.93 million$0.8858.45
Cytosorbents$24.95 million15.43$-19,270,000.00($0.60)-14.83

LeMaitre Vascular has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LeMaitre Vascular and Cytosorbents' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LeMaitre Vascular15.41%12.32%8.45%
Cytosorbents-30.45%-34.37%-19.74%

Institutional and Insider Ownership

84.2% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 39.8% of Cytosorbents shares are owned by institutional investors. 16.5% of LeMaitre Vascular shares are owned by insiders. Comparatively, 5.7% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for LeMaitre Vascular and Cytosorbents, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LeMaitre Vascular04202.33
Cytosorbents00503.00

LeMaitre Vascular currently has a consensus price target of $36.60, suggesting a potential downside of 28.85%. Cytosorbents has a consensus price target of $15.00, suggesting a potential upside of 68.54%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than LeMaitre Vascular.

Summary

LeMaitre Vascular beats Cytosorbents on 10 of the 14 factors compared between the two stocks.


Cytosorbents Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13+0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72+5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76+0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00+0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44+2.0%$1.06 billion$117.23 million55.31Gap Up
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55+0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77+1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61+0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87+1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14+0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
News Coverage
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49+1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94+2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26+0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81+1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00+1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21+0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55+1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12+1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07+0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50+3.9%$415.95 million$4.17 million-17.52News Coverage
Gap Up
Soliton logo
SOLY
Soliton
1.1$18.25+0.1%$386.90 millionN/A-24.33
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73+0.7%$373.97 million$198.38 million24.87
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.20+0.5%$370.85 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50+3.7%$326.02 million$28.15 million-20.21Analyst Downgrade
Gap Up
Neuronetics logo
STIM
Neuronetics
1.5$12.79+2.5%$324.97 million$62.66 million-7.61Gap Up
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54+1.0%$319.17 million$46.90 million27.62News Coverage
DarioHealth logo
DRIO
DarioHealth
1.1$20.62+3.9%$317.45 million$7.56 million-2.58Gap Up
IRadimed logo
IRMD
IRadimed
1.5$24.04+3.0%$295.96 million$38.52 million75.13News Coverage
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.10+2.2%$260.86 million$220,000.0011.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53+0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82+7.1%$199.34 millionN/A182.00Analyst Report
Analyst Revision
News Coverage
Gap Down
TELA Bio logo
TELA
TELA Bio
2.1$13.72+0.0%$198.12 million$15.45 million-4.71
NMRD
Nemaura Medical
0.2$6.96+3.6%$159.59 millionN/A-34.80Gap Up
PolyPid logo
PYPD
PolyPid
1.4$9.33+2.0%$159.04 millionN/A0.00Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.44+0.6%$153.00 million$23.16 million-344.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.66+1.1%$147.07 million$50.71 million-4.56Gap Up
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.20+1.0%$145.02 millionN/A0.00
Avinger logo
AVGR
Avinger
1.3$1.50+0.7%$142.95 million$9.13 million-1.15News Coverage
Gap Up
Beyond Air logo
XAIR
Beyond Air
1.7$5.95+1.8%$121.90 million$1.39 million-3.79
Venus Concept logo
VERO
Venus Concept
1.9$2.24+2.2%$120.90 million$110.41 million-0.67Gap Down
Liquidia logo
LQDA
Liquidia
1.5$2.58+1.9%$111.81 million$8.07 million-1.21Gap Up
Brainsway logo
BWAY
Brainsway
1.3$9.37+0.6%$104.24 million$23.10 million-29.28News Coverage
Pro-Dex logo
PDEX
Pro-Dex
0.7$26.89+0.4%$103.82 million$34.83 million26.97
Nephros logo
NEPH
Nephros
2.0$8.07+3.3%$79.98 million$10.33 million-17.54News Coverage
Gap Up
LENSAR logo
LNSR
LENSAR
1.7$7.02+1.0%$76.75 millionN/A0.00Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.